Compare BCRX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | LMAT |
|---|---|---|
| Founded | 1986 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 1995 | 2006 |
| Metric | BCRX | LMAT |
|---|---|---|
| Price | $8.26 | $97.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $20.82 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 4.2M | 223.4K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ 381.40 | 30.57 |
| EPS | N/A | ★ 0.68 |
| Revenue | $25,186,000.00 | ★ $249,602,000.00 |
| Revenue This Year | N/A | $14.21 |
| Revenue Next Year | $12.55 | $8.88 |
| P/E Ratio | ★ N/A | $146.62 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $6.00 | $79.01 |
| 52 Week High | $11.31 | $118.01 |
| Indicator | BCRX | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 35.56 |
| Support Level | $7.94 | $82.65 |
| Resistance Level | $8.68 | $99.95 |
| Average True Range (ATR) | 0.46 | 4.66 |
| MACD | -0.08 | -0.63 |
| Stochastic Oscillator | 23.34 | 11.95 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.